Albireo Pharma Executives
ALBODelisted Stock | USD 44.15 0.75 1.67% |
Albireo Pharma employs about 130 people. The company is managed by 10 executives with a total tenure of roughly 27 years, averaging almost 2.0 years of service per executive, having 13.0 employees per reported executive. Analysis of Albireo Pharma's management performance can provide insight into the firm performance.
Ronald Cooper CEO President CEO, Director |
Albireo |
Albireo Pharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.2494) % which means that it has lost $0.2494 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9308) %, meaning that it created substantial loss on money invested by shareholders. Albireo Pharma's management efficiency ratios could be used to measure how well Albireo Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Albireo Pharma Workforce Comparison
Albireo Pharma is rated second in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 149,260. Albireo Pharma adds roughly 130 in number of employees claiming only tiny portion of equities under Health Care industry.
The company has Profit Margin (PM) of (2.29) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.15) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.15. Albireo Pharma Notable Stakeholders
An Albireo Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Albireo Pharma often face trade-offs trying to please all of them. Albireo Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Albireo Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Ronald Cooper | President CEO, Director | Profile | |
Simon Harford | CFO, Treasurer | Profile | |
Joan Connolly | Chief Officer | Profile | |
Martha Carter | Chief Regulatory Officer | Profile | |
Michelle Graham | Chief Officer | Profile | |
Jan Mattsson | MD Officer | Profile | |
Kristina Torfgard | VP Head | Profile | |
PerGoran Gillberg | CoFounder Devel | Profile | |
Jason Duncan | Gen Officer | Profile | |
Pamela MPH | Chief Officer | Profile |
About Albireo Pharma Management Performance
The success or failure of an entity such as Albireo Pharma often depends on how effective the management is. Albireo Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Albireo management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Albireo management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts. Albireo Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 130 people.
Albireo Pharma Workforce Analysis
Traditionally, organizations such as Albireo Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Albireo Pharma within its industry.Albireo Pharma Manpower Efficiency
Return on Albireo Pharma Manpower
Revenue Per Employee | 312.1K | |
Revenue Per Executive | 4.1M | |
Net Loss Per Employee | 261.8K | |
Net Loss Per Executive | 3.4M | |
Working Capital Per Employee | 205.9K | |
Working Capital Per Executive | 2.7M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in Albireo Stock
If you are still planning to invest in Albireo Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Albireo Pharma's history and understand the potential risks before investing.
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |